Steps and time to process clinical trials at the cancer therapy evaluation program

Joshua S. Crites, David Dilts, Alan B. Sandler, Steven K. Cheng, Lori B. Ferranti, Amy Y. Wu, Shanda Finnigan, Steven Friedman, Margaret Mooney, Jeffrey Abrams

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose To examine the processes and document the calendar time required for the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) and Central Institutional Review Board (CIRB) to evaluate and approve phase III clinical trials. Methods Process steps were documented by (1) interviewing CTEP and CIRB staff regarding the steps required to activate a trial from initial concept submission to trial activation by a cooperative group, (2) reviewing standard operating procedures, and (3) inspecting trial records and documents for selected trials to identify any additional steps. Calendar time was collected from initial concept submission to activation using retrospective data from the CTEP Protocol and Information Office. Results At least 296 distinct processes are required for phase III trial activation: at least 239 working steps, 52 major decision points, 20 processing loops, and 11 stopping points. Of the 195 trials activated during the January 1, 2000, to December 31, 2007, study period, a sample of 167 (85.6%) was used for gathering timing data. Median calendar days from initial formal concept submission to CTEP to trial activation by a cooperative group was 602 days (interquartile range, 454 to 861 days). This time has not significantly changed over the past 8 years. There is a high variation in the time required to activate a clinical trial. Conclusion Because of their complexity, the overall development time for phase III clinical trials is lengthy, process laden, and highly variable. To streamline the process, a solution must be sought that includes all parties involved in developing trials.

Original languageEnglish (US)
Pages (from-to)1761-1766
Number of pages6
JournalJournal of Clinical Oncology
Volume27
Issue number11
DOIs
StatePublished - Apr 10 2009
Externally publishedYes

Fingerprint

Program Evaluation
Clinical Trials
Phase III Clinical Trials
Research Ethics Committees
Neoplasms
Therapeutics
National Cancer Institute (U.S.)
Calendars

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Crites, J. S., Dilts, D., Sandler, A. B., Cheng, S. K., Ferranti, L. B., Wu, A. Y., ... Abrams, J. (2009). Steps and time to process clinical trials at the cancer therapy evaluation program. Journal of Clinical Oncology, 27(11), 1761-1766. https://doi.org/10.1200/JCO.2008.19.9133

Steps and time to process clinical trials at the cancer therapy evaluation program. / Crites, Joshua S.; Dilts, David; Sandler, Alan B.; Cheng, Steven K.; Ferranti, Lori B.; Wu, Amy Y.; Finnigan, Shanda; Friedman, Steven; Mooney, Margaret; Abrams, Jeffrey.

In: Journal of Clinical Oncology, Vol. 27, No. 11, 10.04.2009, p. 1761-1766.

Research output: Contribution to journalArticle

Crites, JS, Dilts, D, Sandler, AB, Cheng, SK, Ferranti, LB, Wu, AY, Finnigan, S, Friedman, S, Mooney, M & Abrams, J 2009, 'Steps and time to process clinical trials at the cancer therapy evaluation program', Journal of Clinical Oncology, vol. 27, no. 11, pp. 1761-1766. https://doi.org/10.1200/JCO.2008.19.9133
Crites JS, Dilts D, Sandler AB, Cheng SK, Ferranti LB, Wu AY et al. Steps and time to process clinical trials at the cancer therapy evaluation program. Journal of Clinical Oncology. 2009 Apr 10;27(11):1761-1766. https://doi.org/10.1200/JCO.2008.19.9133
Crites, Joshua S. ; Dilts, David ; Sandler, Alan B. ; Cheng, Steven K. ; Ferranti, Lori B. ; Wu, Amy Y. ; Finnigan, Shanda ; Friedman, Steven ; Mooney, Margaret ; Abrams, Jeffrey. / Steps and time to process clinical trials at the cancer therapy evaluation program. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 11. pp. 1761-1766.
@article{21b23a579f6a4e878be3135f64b0d434,
title = "Steps and time to process clinical trials at the cancer therapy evaluation program",
abstract = "Purpose To examine the processes and document the calendar time required for the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) and Central Institutional Review Board (CIRB) to evaluate and approve phase III clinical trials. Methods Process steps were documented by (1) interviewing CTEP and CIRB staff regarding the steps required to activate a trial from initial concept submission to trial activation by a cooperative group, (2) reviewing standard operating procedures, and (3) inspecting trial records and documents for selected trials to identify any additional steps. Calendar time was collected from initial concept submission to activation using retrospective data from the CTEP Protocol and Information Office. Results At least 296 distinct processes are required for phase III trial activation: at least 239 working steps, 52 major decision points, 20 processing loops, and 11 stopping points. Of the 195 trials activated during the January 1, 2000, to December 31, 2007, study period, a sample of 167 (85.6{\%}) was used for gathering timing data. Median calendar days from initial formal concept submission to CTEP to trial activation by a cooperative group was 602 days (interquartile range, 454 to 861 days). This time has not significantly changed over the past 8 years. There is a high variation in the time required to activate a clinical trial. Conclusion Because of their complexity, the overall development time for phase III clinical trials is lengthy, process laden, and highly variable. To streamline the process, a solution must be sought that includes all parties involved in developing trials.",
author = "Crites, {Joshua S.} and David Dilts and Sandler, {Alan B.} and Cheng, {Steven K.} and Ferranti, {Lori B.} and Wu, {Amy Y.} and Shanda Finnigan and Steven Friedman and Margaret Mooney and Jeffrey Abrams",
year = "2009",
month = "4",
day = "10",
doi = "10.1200/JCO.2008.19.9133",
language = "English (US)",
volume = "27",
pages = "1761--1766",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Steps and time to process clinical trials at the cancer therapy evaluation program

AU - Crites, Joshua S.

AU - Dilts, David

AU - Sandler, Alan B.

AU - Cheng, Steven K.

AU - Ferranti, Lori B.

AU - Wu, Amy Y.

AU - Finnigan, Shanda

AU - Friedman, Steven

AU - Mooney, Margaret

AU - Abrams, Jeffrey

PY - 2009/4/10

Y1 - 2009/4/10

N2 - Purpose To examine the processes and document the calendar time required for the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) and Central Institutional Review Board (CIRB) to evaluate and approve phase III clinical trials. Methods Process steps were documented by (1) interviewing CTEP and CIRB staff regarding the steps required to activate a trial from initial concept submission to trial activation by a cooperative group, (2) reviewing standard operating procedures, and (3) inspecting trial records and documents for selected trials to identify any additional steps. Calendar time was collected from initial concept submission to activation using retrospective data from the CTEP Protocol and Information Office. Results At least 296 distinct processes are required for phase III trial activation: at least 239 working steps, 52 major decision points, 20 processing loops, and 11 stopping points. Of the 195 trials activated during the January 1, 2000, to December 31, 2007, study period, a sample of 167 (85.6%) was used for gathering timing data. Median calendar days from initial formal concept submission to CTEP to trial activation by a cooperative group was 602 days (interquartile range, 454 to 861 days). This time has not significantly changed over the past 8 years. There is a high variation in the time required to activate a clinical trial. Conclusion Because of their complexity, the overall development time for phase III clinical trials is lengthy, process laden, and highly variable. To streamline the process, a solution must be sought that includes all parties involved in developing trials.

AB - Purpose To examine the processes and document the calendar time required for the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) and Central Institutional Review Board (CIRB) to evaluate and approve phase III clinical trials. Methods Process steps were documented by (1) interviewing CTEP and CIRB staff regarding the steps required to activate a trial from initial concept submission to trial activation by a cooperative group, (2) reviewing standard operating procedures, and (3) inspecting trial records and documents for selected trials to identify any additional steps. Calendar time was collected from initial concept submission to activation using retrospective data from the CTEP Protocol and Information Office. Results At least 296 distinct processes are required for phase III trial activation: at least 239 working steps, 52 major decision points, 20 processing loops, and 11 stopping points. Of the 195 trials activated during the January 1, 2000, to December 31, 2007, study period, a sample of 167 (85.6%) was used for gathering timing data. Median calendar days from initial formal concept submission to CTEP to trial activation by a cooperative group was 602 days (interquartile range, 454 to 861 days). This time has not significantly changed over the past 8 years. There is a high variation in the time required to activate a clinical trial. Conclusion Because of their complexity, the overall development time for phase III clinical trials is lengthy, process laden, and highly variable. To streamline the process, a solution must be sought that includes all parties involved in developing trials.

UR - http://www.scopus.com/inward/record.url?scp=64649092129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64649092129&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.19.9133

DO - 10.1200/JCO.2008.19.9133

M3 - Article

C2 - 19255315

AN - SCOPUS:64649092129

VL - 27

SP - 1761

EP - 1766

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -